Cantor Fitzgerald boosted its price target on Sequenom Inc. (SQNM) to $29
More News related to SQNM
- Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy
- New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations
- Sequenom Completes Acquisition of CLIA-Certified Laboratory
- UBS Initiates Coverage on Sequenom (SQNM) with a Neutral
- Sequenom (SQNM) Reports Q3 Loss of $0.18
More News related to Analyst Comments
- Sartorius Stedim Biotech GmbH: Acquisition of Wave Biotech AG Wrapped Up
- austriamicrosystems Expands CMOS, High-Voltage, High-Voltage Flash and RF Multi Project Wafer Service for Foundry Customers
- CGGVeritas Announces the Clearance of its Voluntary Exchange Tender Offer for Wavefield Inseis by the Norwegian Competition Authority
- Canasia Industries Corporation: Awarded Additional Coal Permits from Saskatchewan Government
- Final Opinion Regarding a Tender Offer for the Shares of Charle Co., Ltd.
Cantor Fitzgerald boosted its price target on Sequenom Inc. (Nasdaq: SQNM) from $18 to $29, reiterating their Buy rating.
The firm cited, "expectation that Sequenom could complete the acquisition of a CLIA lab by year-end 2008 - a higher revenue/profit business model, in our view - plus increased cash per share and risk reduction due to an improved cash position."
Related Categories
Analyst CommentsStocks Mentioned
+0.26Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
